Transcept to Try Again With Sleep Disorder Drug

Transcept Pharmaceuticals Inc plans to resubmit a new drug application with U.S. regulators for its sleep-disorder drug Intermezzo after a study showed no significant effect on driving after four hours.
Finanz Nachrichten